Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for MRNA Vaccine Development

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2022 Mar 10

PMID 35265614

Authors

Ran Xu

Tong Lu

Jiaying Zhao

Jun Wang

Bo Peng

Linyou Zhang

Affiliations

Soon will be listed here.

Abstract

Cancer vaccines are emerging as a viable strategy for cancer treatment. In the current study, we screened for genes associated with the prognosis of patients with lung adenocarcinoma and positively correlated with antigen-presenting cell infiltration and identified KLRG1 and CBFA2T3 as potential tumor antigens for mRNA vaccines in lung adenocarcinoma (LUAD). Further analyses of immune subtypes revealed that patients with early-stage LUAD, high immune cell infiltration, high immune checkpoint expression, and low tumor mutation burden might benefit from mRNA vaccination. Moreover, we identified four biomarkers that can be used to assess mRNA vaccination suitability. We also identified potentially sensitive anti-cancer drugs for populations not suitable for vaccination by means of anti-cancer drug susceptibility prediction. Overall, we provided a new perspective for mRNA vaccine treatment strategies for LUAD and emphasized the importance of precise and personalized treatments.

Citing Articles

The role of KLRG1: a novel biomarker and new therapeutic target.

Zhang Y, Chen S, Tang X, Peng Y, Jiang T, Zhang X Cell Commun Signal. 2024; 22(1):337.

PMID: 38898461 PMC: 11186184. DOI: 10.1186/s12964-024-01714-7.

CBFA2T3 Is PPARA Sensitive and Attenuates Fasting-Induced Lipid Accumulation in Mouse Liver.

Kim D, Ha S, Gonzalez F Cells. 2024; 13(10.

PMID: 38786053 PMC: 11119203. DOI: 10.3390/cells13100831.

Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma.

Zhang Y, Jia Q, Li F, Luo X, Wang Z, Wang X Sci Rep. 2024; 14(1):7543.

PMID: 38555384 PMC: 10981664. DOI: 10.1038/s41598-024-57910-5.

Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC.

Kiousi E, Lyraraki V, Mardiki G, Stachika N, Damianou A, Malainou C Cancers (Basel). 2023; 15(23).

PMID: 38067293 PMC: 10705317. DOI: 10.3390/cancers15235589.

Research progress of nanovaccine in anti-tumor immunotherapy.

Yao M, Liu X, Qian Z, Fan D, Sun X, Zhong L Front Oncol. 2023; 13:1211262.

PMID: 37692854 PMC: 10484753. DOI: 10.3389/fonc.2023.1211262.

References

Kim J, Eygeris Y, Gupta M, Sahay G . Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021; 170:83-112. PMC: 7837307. DOI: 10.1016/j.addr.2020.12.014. View

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

Tata A, Dodard G, Fugere C, Leget C, Ors M, Rossi B . Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers. Oncoimmunology. 2021; 10(1):1933808. PMC: 8208121. DOI: 10.1080/2162402X.2021.1933808. View

McFall T, Diedrich J, Mengistu M, Littlechild S, Paskvan K, Sisk-Hackworth L . A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. Sci Signal. 2019; 12(600). PMC: 6864030. DOI: 10.1126/scisignal.aaw8288. View

Sansregret L, Vanhaesebroeck B, Swanton C . Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018; 15(3):139-150. DOI: 10.1038/nrclinonc.2017.198. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Geeleher P, Cox N, Huang R . pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014; 9(9):e107468. PMC: 4167990. DOI: 10.1371/journal.pone.0107468. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

Zhou T, Yang P, Tang S, Zhu Z, Li X, Yang Z . Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes. J Oncol. 2021; 2021:5512325. PMC: 8337117. DOI: 10.1155/2021/5512325. View

10.

Huang X, Tang T, Zhang G, Liang T . Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021; 20(1):50. PMC: 7938044. DOI: 10.1186/s12943-021-01342-6. View

11.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

12.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

13.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

14.

Herndler-Brandstetter D, Ishigame H, Shinnakasu R, Plajer V, Stecher C, Zhao J . KLRG1 Effector CD8 T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity. 2018; 48(4):716-729.e8. PMC: 6465538. DOI: 10.1016/j.immuni.2018.03.015. View

15.

Osmani L, Askin F, Gabrielson E, Li Q . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017; 52(Pt 1):103-109. PMC: 5970946. DOI: 10.1016/j.semcancer.2017.11.019. View

16.

Wang Y, Zhang L, Xu Z, Miao L, Huang L . mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Mol Ther. 2017; 26(2):420-434. PMC: 5835019. DOI: 10.1016/j.ymthe.2017.11.009. View

17.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

18.

Zhao Q, Liu L, Lu L, Gui R, Luo Y . A Novel Intercellular Communication-Associated Gene Signature for Prognostic Prediction and Clinical Value in Patients With Lung Adenocarcinoma. Front Genet. 2021; 12:702424. PMC: 8419521. DOI: 10.3389/fgene.2021.702424. View

19.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

20.

Zhang H, Meltzer P, Davis S . RCircos: an R package for Circos 2D track plots. BMC Bioinformatics. 2013; 14:244. PMC: 3765848. DOI: 10.1186/1471-2105-14-244. View